M. Ratcliffe

发表

96ODETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY

B. Han, N. Normanno, R. McCormack, 2015 .

35O_PRINVESTIGATING THE UTILITY OF CIRCULATING-FREE TUMOUR-DERIVED DNA (CTDNA) IN PLASMA FOR THE DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION STATUS IN EUROPEAN AND JAPANESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC): ASSESS STUDY

B. Han, N. Normanno, R. McCormack, 2015 .

Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

M. Rebelatto, L. Siu, Jill Walker, 2018, Clinical Research (Excluding Clinical Trials).

EGFR Mutation Testing Practices within the Asia Pacific Region

S. Toyooka, Y. Yatabe, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

Alan Sharpe, Paul Scorer, Craig Barker, 2017, Clinical Cancer Research.

Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative

Jill Walker, P. Scorer, A. Midha, 2016 .

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

M. Rebelatto, Jill Walker, M. Scott, 2019, Diagnostic Pathology.

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Chao Li, Gang Han, Marius Ilie, 2019, Modern Pathology.

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.

N. Rizvi, P. Dennis, M. Garassino, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

M. Rebelatto, Jill Walker, M. Scott, 2018, Diagnostic Pathology.

A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)

M. Rebelatto, Jill Walker, M. Scott, 2016 .

Cytology for PD-L1 testing: A systematic review.

K. Kerr, J. Gosney, A. Boothman, 2020, Lung cancer.

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

B. Han, N. Normanno, R. McCormack, 2017, Lung cancer.

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

S. Dearden, Jill Walker, James L Sherwood, 2015, Journal of experimental & clinical cancer research : CR.

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

N. Normanno, M. Denis, K. Thress, 2016, Oncotarget.

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour

S. Müller, M. Orr, Jill Walker, 2014, PloS one.

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies with Different Binding Epitopes: Comparison of Seven Clones.

P. Scorer, C. Barker, Michel Vandenberghe, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

S. Dearden, Jill Walker, James L Sherwood, 2015, Journal of experimental & clinical cancer research : CR.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Kevin Mills, Henrik Zetterberg, Niklas Mattsson, 2012, Biomarkers in medicine.

Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC).

M. Rebelatto, T. Powles, S. Ferro, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC).

M. Rebelatto, J. Walker, M. Scott, 2018, Annals of Oncology.

Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.

M. Rebelatto, Jill Walker, M. Scott, 2017 .

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

K. Blennow, M. Carrillo, H. Soares, 2012, Biomarkers in medicine.